About this item:

78 Views | 108 Downloads

Author Notes:

Corresponding author: Dr. Patel , Emory University School of Medicine and Children’s Healthcare of Atlanta, 2015 Uppergate Dr. NE, 3rd floor, Atlanta, GA 30322. Tel 404-727-5905. rmpatel@emory.edu

The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Army, Department of Defense, the U.S Government, or the National Institutes of Health.

The authors have no relevant conflicts of interest.

Subjects:

Research Funding:

This review was supported, in part, by the National Institutes of Health under award numbers KL2 TR000455 and UL1 TR000454 (R.M.P).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Obstetrics & Gynecology
  • Pediatrics
  • Caffeine
  • Apnea
  • Bronchopulmonary dysplasia
  • Premature infant
  • Noninvasive ventilation
  • RANDOMIZED CONTROLLED-TRIAL
  • EXTREMELY PRETERM INFANTS
  • EXTREMELY PREMATURE-INFANTS
  • BRONCHOPULMONARY DYSPLASIA
  • NEONATAL APNEA
  • DOSE CAFFEINE
  • LUNG-FUNCTION
  • NASAL CPAP
  • THERAPY
  • CITRATE

The Role of Caffeine in Noninvasive Respiratory Support

Tools:

Journal Title:

Clinics in Perinatology

Volume:

Volume 43, Number 4

Publisher:

, Pages 773-+

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Caffeine is one of the most commonly prescribed medications in preterm neonates and is widely used to treat or prevent apnea of prematurity. Caffeine therapy is safe, effectively decreases apnea, and improves short- and long-term outcomes in preterm infants. In this review, the authors summarize the role of caffeine therapy for preterm infants receiving noninvasive respiratory support. As caffeine is already widely used, recent data are summarized that may guide clinicians in optimizing the use of caffeine therapy, with a review of the timing of initiation, dose, and duration of therapy.

Copyright information:

© 2016 Elsevier Inc.

Export to EndNote